MX2024005981A - Derivados funcionalizados deuterados de a-alanina, en particular para el tratamiento de enfermedades neurologicas. - Google Patents
Derivados funcionalizados deuterados de a-alanina, en particular para el tratamiento de enfermedades neurologicas.Info
- Publication number
- MX2024005981A MX2024005981A MX2024005981A MX2024005981A MX2024005981A MX 2024005981 A MX2024005981 A MX 2024005981A MX 2024005981 A MX2024005981 A MX 2024005981A MX 2024005981 A MX2024005981 A MX 2024005981A MX 2024005981 A MX2024005981 A MX 2024005981A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- neurological diseases
- deuterated
- alanine
- functionalized derivatives
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 150000001294 alanine derivatives Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL439639A PL244897B1 (pl) | 2021-11-24 | 2021-11-24 | Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych |
| PCT/PL2022/050083 WO2023096512A1 (en) | 2021-11-24 | 2022-11-24 | DEUTERATED FUNCTIONALIZED DERIVATIVES OF α-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005981A true MX2024005981A (es) | 2024-06-28 |
Family
ID=84980841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005981A MX2024005981A (es) | 2021-11-24 | 2022-11-24 | Derivados funcionalizados deuterados de a-alanina, en particular para el tratamiento de enfermedades neurologicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250042848A1 (https=) |
| EP (1) | EP4436954A1 (https=) |
| JP (1) | JP2024543135A (https=) |
| KR (1) | KR20240110038A (https=) |
| CN (1) | CN118302410A (https=) |
| AU (1) | AU2022395821A1 (https=) |
| CA (1) | CA3236670A1 (https=) |
| MX (1) | MX2024005981A (https=) |
| PL (1) | PL244897B1 (https=) |
| WO (1) | WO2023096512A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085878A1 (en) * | 2023-10-20 | 2025-04-24 | Altay Therapeutics, Inc. | N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL244071B1 (pl) * | 2019-01-07 | 2023-11-27 | Univ Jagiellonski | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
| PL240297B1 (pl) * | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
-
2021
- 2021-11-24 PL PL439639A patent/PL244897B1/pl unknown
-
2022
- 2022-11-24 EP EP22843893.3A patent/EP4436954A1/en active Pending
- 2022-11-24 AU AU2022395821A patent/AU2022395821A1/en active Pending
- 2022-11-24 MX MX2024005981A patent/MX2024005981A/es unknown
- 2022-11-24 WO PCT/PL2022/050083 patent/WO2023096512A1/en not_active Ceased
- 2022-11-24 US US18/711,775 patent/US20250042848A1/en active Pending
- 2022-11-24 CA CA3236670A patent/CA3236670A1/en active Pending
- 2022-11-24 JP JP2024531057A patent/JP2024543135A/ja active Pending
- 2022-11-24 CN CN202280077941.8A patent/CN118302410A/zh active Pending
- 2022-11-24 KR KR1020247020140A patent/KR20240110038A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024543135A (ja) | 2024-11-19 |
| CA3236670A1 (en) | 2023-06-01 |
| PL244897B1 (pl) | 2024-03-25 |
| WO2023096512A1 (en) | 2023-06-01 |
| KR20240110038A (ko) | 2024-07-12 |
| AU2022395821A1 (en) | 2024-06-06 |
| EP4436954A1 (en) | 2024-10-02 |
| US20250042848A1 (en) | 2025-02-06 |
| PL439639A1 (pl) | 2023-05-29 |
| CN118302410A (zh) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ610526A (en) | Deuterium enriched rasagiline | |
| NO20071271L (no) | Aryl-substituerte polyakryliske aminer, fremgangsmate for fremstilling av disse og anvendelse som et medikament. | |
| NO20076055L (no) | Imidazo- og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I | |
| DK1771178T3 (da) | Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande | |
| MX2009010899A (es) | Prediccion de la supervivencia al post-tratamiento en pacientes de cancer con micro-rnas. | |
| NO20076134L (no) | Benzamidderivater og anvendelser derav | |
| SG10201406297TA (en) | Methods for treating progressive multiple sclerosis | |
| EA201391705A1 (ru) | Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
| NO20056039L (no) | Forbedrede cytotoksiske midler omfattende nye maytansinoider | |
| CR20140203A (es) | Derivados de octahidro-pirrolo (3,4-b) pirrol | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
| MX2024005981A (es) | Derivados funcionalizados deuterados de a-alanina, en particular para el tratamiento de enfermedades neurologicas. | |
| MX2011006843A (es) | Dihidropiridona-amidas como moduladores de p2x7. | |
| MX2009005813A (es) | Procedimiento para la preparacion de betamimeticos. | |
| NO20075557L (no) | Krystaller av morfinanderivat og fremgangsmate for fremstilling derav | |
| CY1114844T1 (el) | Ολιγο-νουκλεοτιδιο (oligonucleotide) και συνθεσεις που το περιλαμβανουν για την θεραπεια νεοπλασματος β κυτταρων | |
| UY28255A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger | |
| MY203645A (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| NZ596851A (en) | Methods of treating hepatic encephalopathy | |
| MX2020012980A (es) | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. | |
| MX2009007058A (es) | Compuesto triciclico y uso farmaceutico del mismo. | |
| MX2009006078A (es) | Compuesto triciclico y su uso medico. | |
| SG158909A1 (en) | Management of hydrogen in hydrogen-containing streams from hydrogen sources with rapid cycle pressure swing adsorption | |
| EA201000433A1 (ru) | Лечение вазомоторных симптомов | |
| MX2023009249A (es) | Método para prevenir, tratar o mejorar la colitis ulcerosa. |